RESUMO
PURPOSE: In this study, we report the 24-month patient-reported outcomes of the randomized phase 2 CHIRP trial that compared conventional and hypofractionated radiation therapy (RT) in the treatment of high-risk prostate cancer. METHODS AND MATERIALS: Men with high-risk localized prostate cancer were randomized to either conventional (78 Gy/39 fractions) or hypofractionated RT (68 Gy/25 fractions). All patients received pelvic nodal RT and adjuvant androgen deprivation therapy. Quality of life (QoL) data were collected through the expanded prostate cancer index composite and the short-form 12 (SF-12) health-related QoL questionnaire at baseline and at 3, 6, 12, 18, and 24 months posttreatment. We assessed change from baseline to account for differences in baseline comorbidities. Independent t test was used to identify differences between the 2 groups. RESULTS: Ninety-six participants were included in the QoL analysis, 49 in the hypofractionation arm and 47 in the standard fractionation arm. Urinary and sexual scores were similar between the 2 arms at all time points. Bowel bother scores exhibited a consistent trend favoring the standard arm from 3- to 18-months posttreatment and were statistically significant at 12 months (Pâ¯=â¯.016). SF-12 physical component scores showed a consistent trend favoring the hypofractionation arm from 6- to 18-months posttreatment and were statistically significant at 18 months (Pâ¯=â¯.017). At 24 months, there were no significant differences in QoL scores between the 2 groups. CONCLUSIONS: At 24 months post-RT, there were no major differences in patient-reported QoL between standard and hypofractionated RT. Early statistically significant differences in bowel bother and SF-12 physical component scores were no longer present at 24 months.
Assuntos
Neoplasias da Próstata , Hipofracionamento da Dose de Radiação , Antagonistas de Androgênios , Humanos , Masculino , Medidas de Resultados Relatados pelo Paciente , Neoplasias da Próstata/radioterapia , Qualidade de VidaRESUMO
OBJECTIVE: This study intends to develop an accurate, real-time tumor tracking algorithm for the automated radiation therapy for cancer treatment using Graphics Processing Unit (GPU) computing. Although a previous moving mesh based tumor tracking approach has been shown to be successful in delineating the tumor regions from a sequence of magnetic resonance image, the algorithm is computationally intensive and its computation time on standard Central Processing Unit (CPU) processors is too slow to be used clinically especially for automated radiation therapy system. METHOD: A re-implementation of the algorithm on a low-cost parallel GPU-based computing platform is utilized to accelerate this computation at a speed that is amicable to clinical usages. Several components in the registration algorithm such as the computation of similarity metric are inherently parallel which fits well with the GPU parallel processing capabilities. Solving a partial differential equation numerically to generate the mesh deformation is one of the computationally intensive components which has been accelerated by utilizing a much faster shared memory on the GPU. RESULTS: Implemented on an NVIDIA Tesla K40c GPU, the proposed approach yielded a computational acceleration improvement of over 5 times its implementation on a CPU. The proposed approach yielded an average Dice score of 0.87 evaluated over 600 images acquired from six patients. CONCLUSION: This study demonstrated that the GPU computing approach can be used to accelerate tumor tracking for automated radiation therapy for mobile lung tumors. Clinical Impact: Accurately tracking mobile tumor boundaries in real-time is important to automate radiation therapy and the proposed study offers an excellent option for fast tumor region tracking for cancer treatment.
RESUMO
OBJECTIVE: To assess late toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated radiation treatment with androgen suppression therapy. METHODS: Sixty high-risk prostate cancer patients were enrolled. IMRT prescription was 68 Gy/25 fractions (2.7 Gy/fraction) to the prostate and proximal seminal vesicles (SV). The pelvic lymph nodes (PLN) and distal SV concurrently received 45 Gy/25 fractions (1.8 Gy/fraction). The patients were treated with helical TomoTherapy-based IMRT and underwent daily megavoltage CT image-guided verification before each treatment. RTOG Toxicity scores were recorded for a 5-year period. RESULTS: Sixty patients completed RT with median follow-up of 63 months (range, 7 to 80 mo).At 5 years follow-up timepoint: Grade (G)2 and G3 late genitourinary toxicity was experienced in 7 (17.0%) and 1 (2.44%), respectively; gastrointestinal G2 as highest toxicity recorded in only 1 (2.44%) patient. There was no G3 gastrointestinal toxicity recorded at this timepoint.With 63-month median follow-up (mean of 65.41±1.72 mo), the 5-year overall survival was 86.67%; 5 years freedom from biochemical failure was 91.67% and freedom from clinical failure was 96.67%. CONCLUSIONS: Dose escalation and hypofractionated radiation treatment with IMRT treating the prostate and proximal SV concurrently with the pelvic lymph nodes and distal SV and long-term androgen suppression therapy is well tolerated with respect to acute and late toxicity with 5-year actuarial overall survival 86.67%, freedom from biochemical failure 91.38%, and freedom from clinical failure 96.67%. Longer follow-up will provide more information on 10-year survival outcomes.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Leuprolida/uso terapêutico , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/radioterapia , Hipofracionamento da Dose de Radiação , Radioterapia de Intensidade Modulada , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Medição de Risco , Fatores de TempoRESUMO
PURPOSE: To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM). METHODS AND MATERIALS: Adult patients with GBM and KPS > 70 were prospectively enrolled between 2005 and 2007 in this phase I study. The Fibonacci dose escalation protocol was implemented to establish a safe radiation fractionation regimen. The protocol defined radiation therapy (RT) dose level I as 54.4 Gy in 20 fractions over 4 weeks and dose level II as 60 Gy in 22 fractions over 4.5 weeks. Concurrent TMZ followed by adjuvant TMZ was given according to the Stupp regimen. The primary endpoints were feasibility and safety of Hypo-IMRT with concurrent TMZ. Secondary endpoints included progression free survival (PFS), pattern of failure, overall survival (OS) and incidence of pseudoprogression. The latter was defined as clinical or radiological suggestion of tumour progression within three months of radiation completion followed by spontaneous recovery of the patient. RESULTS: A total of 25 patients were prospectively enrolled with a median follow-up of 12.4 months. The median age at diagnosis was 53 years. Based on recursive partitioning analysis (RPA) criteria, 16%, 52% and 32% of the patients were RPA class III, class IV and class V, respectively. All patients completed concurrent RT and TMZ, and 19 patients (76.0%) received adjuvant TMZ. The median OS was 15.67 months (95% CI 11.56 - 20.04) and the median PFS was 6.7 months (95% CI 4.0 - 14.0). The median time between surgery and start of RT was 44 days (range of 28 to 77 days). Delaying radiation therapy by more than 6 weeks after surgery was an independent prognostic factor associated with a worse OS (4.0 vs. 16.1 months, P = 0.027). All recurrences occurred within 2 cm of the original gross tumour volume (GTV). No cases of pseudoprogression were identified in our cohort of patients. Three patients tolerated dose level I with no dose limiting toxicity and hence the remainder of the patients were treated with dose level II according to the dose escalation protocol. Grade 3-4 hematological toxicity was limited to two patients and one patient developed Grade 4 Pneumocystis jiroveci pneumonia. CONCLUSION: Hypo-IMRT using HT given with concurrent TMZ is feasible and safe. The median OS and PFS are comparable to those observed with conventional fractionation. Hypofractionated radiation therapy offers the advantage of a shorter treatment period which is imperative in this group of patients with limited life expectancy.
Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Braquiterapia , Neoplasias Encefálicas/terapia , Quimiorradioterapia , Dacarbazina/análogos & derivados , Glioblastoma/terapia , Planejamento da Radioterapia Assistida por Computador , Radioterapia de Intensidade Modulada , Adulto , Idoso , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/patologia , Quimioterapia Adjuvante , Dacarbazina/uso terapêutico , Fracionamento da Dose de Radiação , Feminino , Seguimentos , Glioblastoma/mortalidade , Glioblastoma/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/terapia , Estadiamento de Neoplasias , Prognóstico , Estudos Prospectivos , Radioterapia Conformacional , Taxa de Sobrevida , Temozolomida , Adulto JovemRESUMO
The purpose of this study is to evaluate the accuracy and precision of the Clarity 3D ultrasound system to track prostate gland positional variations due to setup error and organ motion. Seventeen patients (n = 17) undergoing radical external beam radiation therapy for localized prostate cancer were studied. Subsequent to initial reference ultrasound and planning CT scans, each patient underwent seven repeat weekly tracking CT and ultrasound (US) scans during the course of treatment. Variations in the location of the prostate between reference and tracking scans were measured. Differences reported by CT and ultrasound scans are compared. Ultrasound tracking was initially performed clinically by a group of trained general users. Retrospective prostate localization was then performed by a trained dedicated user upon the original raw data set and also a reduced data set derived from the original by an expert user from Resonant Medical. Correlation accuracy between ultrasound and CT shifts acquired and delineated by a pool of trained general users was deemed unacceptable for radiotherapy purposes. A mean discrepancy between CT and US localizations of greater than 10 mm, with a 5 mm or greater discrepancy rate of nearly 90%, was observed. Retrospective analysis by a dedicated user of both the original and Resonant Medical reduced data sets yielded mean CT-Us discrepancies of 8.7 mm and 7.4 mm, respectively. Unfortunately, the 5 mm or greater CT-US discord rate for these retrospective analyses failed to drop below 80%. The greatest disparity between CT and ultrasound was consistently observed in the superior-inferior direction, while greatest agreement was achieved in the lateral dimension. Despite an expert reanalysis of the original data, the Clarity ultrasound system failed to deliver an acceptable level of geometric accuracy required for modern radiotherapy purposes.
Assuntos
Próstata/diagnóstico por imagem , Neoplasias da Próstata/diagnóstico por imagem , Neoplasias da Próstata/radioterapia , Humanos , Masculino , Radioterapia Guiada por Imagem , Estudos Retrospectivos , Tomografia Computadorizada por Raios X/métodos , Ultrassom , UltrassonografiaRESUMO
The metabolic content of urine from NIH III nude mice (n = 22) was analysed before and after inoculation with human glioblastoma multiforme (GBM) cancer cells. An age- and gender-matched control population (n = 14) was also studied to identify non-tumour-related changes. Urine samples were collected daily for 6 weeks, beginning 1 week before cell injection. Metabolite concentrations were obtained via targeted profiling with Chenomx Suite 5.1, based on nuclear magnetic resonance (NMR) spectra acquired on an Oxford 800 MHz cold probe NMR spectrometer. The Wilcoxon rank sum test was used to evaluate the significance of the change in metabolite concentration between the two time points. Both the metabolite concentrations and the ratios of pairs of metabolites were studied. The complicated inter-relationships between metabolites were assessed through partial least-squares discriminant analysis (PLS-DA). Receiver operating characteristic (ROC) curves were generated for all variables and the area under the curve (AUC) calculated. The data indicate that the number of statistically significant changes in metabolite concentrations was more pronounced in the tumour-bearing population than in the control animals. This was also true of the ratios of pairs of metabolites. ROC analysis suggests that the ratios were better able to differentiate between the pre- and post-injection samples compared to the metabolite concentrations. PLS-DA models produced good separation between the populations and had the best AUC results (all models exceeded 0.937). These results demonstrate that metabolomics may be used as a screening tool for GBM cells grown in xenograft models in mice.
Assuntos
Glioblastoma/diagnóstico , Glioblastoma/urina , Metaboloma , Urinálise/métodos , Animais , Linhagem Celular Tumoral , Transformação Celular Neoplásica , Glioblastoma/metabolismo , Glioblastoma/patologia , Humanos , Injeções , Camundongos , Análise Multivariada , Transplante de Neoplasias , Curva ROC , Transplante HeterólogoRESUMO
This study was aimed at the applications of an ex vivo assays to characterization of CEM (Human T-Lymphoblastoid) cells. CEM cells were cultured in three dimensional (3-D) geometry in the Hollow Fibre Bioreactor (HFB) device. The cells were treated with Herceptin, anti-HER-2 (clone CB-11) and lipoplex containing lipofectamine (LipA) and plasmid DNA. To identify the response to treatment, the viability was established using Trypan blue assays. Magnetic resonance imaging (MRI) at 9.4Tesla (T) was applied for localization of the cells in the HFB device. The structural changes in the cells associated with treatment were examined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The tryptic peptides and glycopeptides detected in treated cells provided evidence of the efficacy of antibody binding to the receptor. The results of the study confirmed that cells growth significantly decreased after treatment with antibodies and transfection with lipoplex.
Assuntos
Linfócitos T/citologia , Sequência de Aminoácidos , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais Humanizados , Reatores Biológicos , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Glicopeptídeos/análise , Humanos , Lipídeos/farmacologia , Imageamento por Ressonância Magnética , Dados de Sequência Molecular , Fragmentos de Peptídeos/análise , Receptor ErbB-2/antagonistas & inibidores , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz , Linfócitos T/química , Linfócitos T/efeitos dos fármacos , TrastuzumabRESUMO
PURPOSE: To report acute toxicity resulting from radiotherapy (RT) dose escalation and hypofractionation using intensity-modulated RT (IMRT) treatment combined with androgen suppression in high-risk prostate cancer patients. METHODS AND MATERIALS: Sixty patients with a histological diagnosis of high-risk prostatic adenocarcinoma (having either a clinical Stage of > or =T3a or an initial prostate-specific antigen [PSA] level of > or =20 ng/ml or a Gleason score of 8 to 10 or a combination of a PSA concentration of >15 ng/ml and a Gleason score of 7) were enrolled. RT prescription was 68 Gy in 25 fractions (2.72 Gy/fraction) over 5 weeks to the prostate and proximal seminal vesicles. The pelvic lymph nodes and distal seminal vesicles concurrently received 45 Gy in 25 fractions. The patients were treated with helical TomoTherapy-based IMRT and underwent daily megavoltage CT image-guided verification prior to each treatment. Acute toxicity scores were recorded weekly during RT and at 3 months post-RT, using Radiation Therapy Oncology Group acute toxicity scales. RESULTS: All patients completed RT and follow up for 3 months. The maximum acute toxicity scores were as follows: 21 (35%) patients had Grade 2 gastrointestinal (GI) toxicity; 4 (6.67%) patients had Grade 3 genitourinary (GU) toxicity; and 30 (33.33%) patients had Grade 2 GU toxicity. These toxicity scores were reduced after RT; there were only 8 (13.6%) patients with Grade 1 GI toxicity, 11 (18.97%) with Grade 1 GU toxicity, and 5 (8.62%) with Grade 2 GU toxicity at 3 months follow up. Only the V60 to the rectum correlated with the GI toxicity. CONCLUSION: Dose escalation using a hypofractionated schedule to the prostate with concurrent pelvic lymph node RT and long-term androgen suppression therapy is well tolerated acutely. Longer follow up for outcome and late toxicity is required.
Assuntos
Adenocarcinoma/radioterapia , Neoplasias da Próstata/radioterapia , Radioterapia de Intensidade Modulada/efeitos adversos , Adenocarcinoma/sangue , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Idoso , Idoso de 80 Anos ou mais , Antagonistas de Androgênios/uso terapêutico , Terapia Combinada , Fracionamento da Dose de Radiação , Trato Gastrointestinal/efeitos da radiação , Humanos , Leuprolida/uso terapêutico , Irradiação Linfática/efeitos adversos , Irradiação Linfática/métodos , Masculino , Pessoa de Meia-Idade , Pelve , Estudos Prospectivos , Próstata/efeitos da radiação , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/patologia , Lesões por Radiação/patologia , Radioterapia de Intensidade Modulada/métodos , Reto/efeitos da radiação , Glândulas Seminais/efeitos da radiação , Bexiga Urinária/efeitos da radiação , Sistema Urogenital/efeitos da radiaçãoRESUMO
The effective targeting of malignant cell surface antigens is essential in cancer therapy. Resistance to treatment and rapid invasion of cancer cells are the main causes of cancer mortality. Despite intense research efforts, treatments often have demonstrated insufficient outcomes in clinical applications. The aim of the present study was to determine whether combined administration of monoclonal antibody (Herceptin, trastuzumab) and anti-HER-2 (clone CB11) with hyaluronic acid (HA) and lipoplex (containing lipofectamine (LipA) and plasmid DNA) can produce a synergistic reaction to increase the therapeutic effect of monoclonal antibodies. To assess the treatment response, we cultured a 3-D MCF-7 cell line overexpressing HER-2 and CD44 receptors. The high density 3-D cell aggregation in the hollow fiber bioreactor (HFB) used for the cell culture was monitored with the use of proton magnetic resonance imaging ((1)H MRI). In addition, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was used in combination with HPLC (high performance liquid chromatography) to evaluate structural changes in the proteins contained in treated cells. The study showed that incorporation of antibodies into targeted lipoplex results in more efficient delivery of the complex to tumor cells. The viability of cells decreased mostly due to cellular uptake of lipoplex and binding of the antibodies to the cellular surface receptor. The data also demonstrate that HA could be used to enhance treatment efficacy of trastuzumab and anti-HER-2 (clone CB11) in breast cancer cell cultures.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias da Mama/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/imunologia , Neoplasias da Mama/imunologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão/métodos , DNA/administração & dosagem , Resistencia a Medicamentos Antineoplásicos , Sinergismo Farmacológico , Feminino , Humanos , Receptores de Hialuronatos/imunologia , Ácido Hialurônico/administração & dosagem , Lipídeos/administração & dosagem , Imageamento por Ressonância Magnética/métodos , Plasmídeos/administração & dosagem , Receptor ErbB-2/imunologia , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos , TrastuzumabRESUMO
It was shown, that cultured ex vivo human T-Lymphoblastoid (CEM) cells respond to synthesized thiocolchicine and fluorine thiocolchicine derivatives. The preparation of derivatives with substitution at C-3 and C-7 is described. All compounds were used at concentration from 1 nM to 1000 nM. Inhibitory effects of these compounds were examined in the three-dimensional (3-D) culture and cells morphology during treatment was monitored using 9.4 T MRI system. We performed studies of these compounds in CEM cells ex vivo using 1H and 19F Magnetic Resonance Imaging (MRI), 19F Magnetic Resonance Spectroscopy (MRS), High Performance Liquid Chromatography coupled with Ultra Violet (HPLC-UV) and Electron Impact Mass Spectrometry (EIMS). The results of the multi-technique approach are consistent with the fact that the new derivatives are more efficient than colchicine and thiocolchicine ex vivo.
Assuntos
Colchicina/análogos & derivados , Linfócitos T/efeitos dos fármacos , Reatores Biológicos , Células Cultivadas , Cromatografia Líquida de Alta Pressão , Colchicina/química , Colchicina/farmacologia , Flúor/química , Humanos , Imageamento por Ressonância Magnética , Espectrometria de Massas , Espectrofotometria Ultravioleta , Linfócitos T/imunologiaRESUMO
PURPOSE: A planning study to compare helical tomotherapy (HT) and intensity-modulated radiotherapy (IMRT) for the treatment of anal canal cancer. MATERIALS AND METHODS: Sixteen (8 males and 8 females) patients with anal cancer previously treated radically were identified. HT and IMRT plans were generated and dosimetric comparisons of the plans were performed. The planning goals were to deliver 54Gy to the tumor (PTV(54Gy)) and 48Gy to the nodes at risk (PTV(Node)) in 30 fractions. RESULTS: PTVs: HT plans were more homogeneous for both men and women. Male patients: HT vs. IMRT: D(max): 55.87+/-0.58 vs. 59.17+/-3.24 (p=0.036); D(min): 52.91+/-0.36 vs. 44.09+/-6.84 (p=0.012); female patients: HT vs. IMRT: D(max): 56.14+/-0.71 vs. 59.47+/-0.81 (p=0.012); D(min): 52.36+/-0.87 vs. 50.97+/-1.42 (p=0.028). OARs: In general, HT plans delivered a lower dose to the peritoneal cavity, external genitalia and the bladder and IMRT plans resulted in greater sparing of the pelvic bones (iliac crest/femur) for both men and women. Iliac crest/femur: the difference was significant only for the mean V10Gy of iliac crest in women (p< or =0.012). External genitalia: HT plans achieved better sparing in women compared to men (p< or =0.046). For men, the mean doses were 18.96+/-3.17 and 15.72+/-3.21 for the HT and IMRT plan, respectively (p< or =0.017). Skin: both techniques achieved comparable sparing of the non-target skin (p=NS). CONCLUSIONS: HT and IMRT techniques achieved comparable target dose coverage and organ sparing, whereas HT plans were more homogeneous for both men and women.
Assuntos
Neoplasias do Ânus/radioterapia , Radioterapia de Intensidade Modulada , Tomografia Computadorizada Espiral , Feminino , Humanos , Masculino , Doses de Radiação , Resultado do TratamentoRESUMO
The paper describes ex vivo applications of colchicine derivatives for the treatment of human T-Lymphoblastoid (CEM) cells. Moreover, the role of the substitutions of ring A at C-1 and C-7 side chain of colchicine analogues was probed by the synthesis and examination of their effects on the three-dimensional (3-D) CEM cells' growth. The CEM cells were cultured in the hollow fiber bioreactor (HFB) device. We used (1)H and (19)F magnetic resonance imaging (MRI) to monitor changes in 3-D CEM cell culture. (19)F MRI was used for visualization of the cellular uptake of new fluorine derivatives. Before and after treatment CEM cells profile was investigated with high performance liquid chromatography (HPLC-UV).
Assuntos
Cromatografia Líquida de Alta Pressão , Colchicina/análogos & derivados , Imageamento por Ressonância Magnética , Espectrofotometria Ultravioleta , Linfócitos T/citologia , Reatores Biológicos , Técnicas de Cultura de Células , Sobrevivência Celular , Colchicina/síntese química , Colchicina/metabolismo , Flúor/química , Flúor/metabolismo , Humanos , Linfócitos T/imunologiaRESUMO
The aim of this study was to determine the role of delta-tocopherol in breast cancer cell growth ex vivo. Human gland mammary adenocarcinoma (MCF-7) and human T-lymphoblastoid (CEM) cells were cultured in the presence of delta-tocopherol at various concentrations (0-750 microM) for 5 days. We have grown 3D ex vivo breast cancer cell cultures in the hollow fiber bioreactor (HFBR). (19)F magnetic resonance imaging (MRI) was used to evaluate oxygen concentration in the cell suspension and thus its viability.
Assuntos
Neoplasias da Mama/patologia , Imageamento por Ressonância Magnética/métodos , Tocoferóis/farmacologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Feminino , Flúor , Humanos , Oxigênio/análiseRESUMO
PURPOSE: To determine from the number of trials, n, and the number of observed successes, k the most probable value, the variance and the confidence limits of the probability of success, p, in animal experiments and clinical studies subject to binomial statistics. METHOD: In such experiments the probability of success is an unknown parameter. The Bayesian approach to the problem is advocated, based on constructed distribution of the probability of success. RESULTS: A simple Matlab code for the calculation of the confidence limits according to the proposed method is provided. The most probable, the mean, the variance and the confidence limits are calculated applying the usual definitions of these characteristics. CONCLUSION: The proposed method works for any number of trials--large and small and all possible values of the number of successes, including k=0 and k=n, providing exact formulae for the calculation of the confidence limits in all cases.
Assuntos
Projetos de Pesquisa , Algoritmos , Animais , Teorema de Bayes , Estudos de Coortes , Interpretação Estatística de Dados , Humanos , Modelos Estatísticos , Modelos Teóricos , Probabilidade , Reprodutibilidade dos Testes , Software , Processos EstocásticosRESUMO
PURPOSE: To evaluate the feasibility of skin-sparing by configuring it as an organ-at-risk (OAR) while delivering whole-breast intensity-modulated radiotherapy (IMRT) in early breast cancer. METHODS AND MATERIALS: Archival computed tomography scan images of 14 left-sided early-breast tumor patients who had undergone lumpectomy were selected for this study. Skin was contoured as a 4- to 5-mm strip extending from the patient outline to anterior margin of the breast planning target volume (PTV). Two IMRT plans were generated by the helical tomotherapy approach to deliver 50 Gy in 25 fractions to the breast alone: one with skin dose constraints (skin-sparing plan) and the other without (non-skin-sparing plan). Comparison of the plans was done using a two-sided paired Student t test. RESULTS: The mean skin dose and volume of skin receiving 50 Gy were significantly less with the skin-sparing plan compared with non-skin-sparing plan (42.3 Gy vs. 47.7 Gy and 12.2% vs. 57.8% respectively; p < 0.001). The reduction in skin dose was confirmed by TLD measurements in anthropomorphic phantom using the same plans. Dose-volume analyses for other OARs were similar in both plans. CONCLUSIONS: By configuring the skin as an OAR, it is possible to achieve skin dose reduction while delivering whole-breast IMRT without compromising dose profiles to PTV and OARs.
Assuntos
Neoplasias da Mama/radioterapia , Lesões por Radiação/prevenção & controle , Radioterapia de Intensidade Modulada , Pele/efeitos da radiação , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Carcinoma Ductal de Mama/patologia , Carcinoma Ductal de Mama/radioterapia , Carcinoma Ductal de Mama/cirurgia , Estudos de Viabilidade , Feminino , Humanos , Mastectomia Segmentar , Dosagem Radioterapêutica , Carga TumoralRESUMO
BACKGROUND AND PURPOSE: To evaluate the feasibility of sparing the parotid glands and surgically transferred submandibular gland (SMG) by intensity modulated radiotherapy (IMRT) in post-operative cases of head and neck cancer (HNC). MATERIALS AND METHODS: Ten patients (larynx-2, base of tongue-4, tonsil-3, and unknown primary-1; pathologic stages III-IV) who underwent SMG transfers on the side of N0 neck along with definitive surgery were selected for this study. IMRT planning was done retrospectively using helical tomotherapy approach. Planning objective was to deliver 60 Gy to PTV1 and 54 Gy to PTV2 while maintaining the mean dose to the total parotid volume (TPV) and SMG less than 26 Gy. RESULTS: The mean dose (+/-SD) to the TPV and SMG were 25+/-0.6 Gy and 23+/-1.9 Gy, respectively. The D(95) for PTV1 and PTV2 were 59.9+/-0.1 Gy and 54.9+/-0.3 Gy, respectively, satisfying our planning goal for PTV coverage. The D(99) for PTV1 and PTV2 were 58.2+/-0.7 Gy and 49.5+/-2.2 Gy, respectively, showing that sparing the salivary glands did not result in underdosing of the PTVs. CONCLUSIONS: By combining the gland transfer and IMRT, the mean dose to TPV and transferred SMG could be reduced to less than 26 Gy in post-operative patients of HNC.
Assuntos
Neoplasias de Cabeça e Pescoço/radioterapia , Glândula Parótida/efeitos da radiação , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia de Intensidade Modulada/métodos , Glândula Submandibular/efeitos da radiação , Tomografia Computadorizada Espiral/métodos , Terapia Combinada , Neoplasias de Cabeça e Pescoço/cirurgia , Humanos , Lesões por Radiação/prevenção & controle , Estudos Retrospectivos , Glândula Submandibular/cirurgiaRESUMO
PURPOSE: To present a technique that can be implemented in-house to evaluate the efficacy of immobilization and image-guided setup of patients with different treatment sites on helical tomotherapy. This technique uses an analysis of alignment shifts between kilovoltage computed tomography and post-treatment megavoltage computed tomography images. The determination of the shifts calculated by the helical tomotherapy software for a given site can then be used to define appropriate planning target volume internal margins. METHODS AND MATERIALS: Twelve patients underwent post-treatment megavoltage computed tomography scans on a helical tomotherapy machine to assess patient setup fidelity and net intrafraction motion. Shifts were studied for the prostate, head and neck, and glioblastoma multiforme. Analysis of these data was performed using automatic and manual registration of the kilovoltage computed tomography and post-megavoltage computed tomography images. RESULTS: The shifts were largest for the prostate, followed by the head and neck, with glioblastoma multiforme having the smallest shifts in general. It appears that it might be more appropriate to use asymmetric planning target volume margins. Each margin value reported is equal to two standard deviations of the average shift in the given direction. CONCLUSION: This method could be applied using individual patient post-image scanning and combined with adaptive planning to reduce or increase the margins as appropriate.
Assuntos
Neoplasias Encefálicas/radioterapia , Glioblastoma/radioterapia , Neoplasias de Cabeça e Pescoço/radioterapia , Movimento , Neoplasias da Próstata/radioterapia , Planejamento da Radioterapia Assistida por Computador/métodos , Neoplasias Encefálicas/patologia , Glioblastoma/patologia , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Masculino , Fenômenos Físicos , Física , Neoplasias da Próstata/patologia , Tecnologia Radiológica/métodos , Tomografia Computadorizada Espiral , Carga TumoralRESUMO
The present study evaluates the performance of a newly released photon-beam dose calculation algorithm that is incorporated into an established treatment planning system (TPS). We compared the analytical anisotropic algorithm (AAA) factory-commissioned with "golden beam data" for Varian linear accelerators with measurements performed at two institutions using 6-MV and 15-MV beams. The TG-53 evaluation regions and criteria were used to evaluate profiles measured in a water phantom for a wide variety of clinically relevant beam geometries. The total scatter factor (TSF) for each of these geometries was also measured and compared against the results from the AAA. At one institute, TLD measurements were performed at several points in the neck and thoracic regions of a Rando phantom; at the other institution, ion chamber measurements were performed in a CIRS inhomogeneous phantom. The phantoms were both imaged using computed tomography (CT), and the dose was calculated using the AAA at corresponding detector locations. Evaluation of measured relative dose profiles revealed that 97%, 99%, 97%, and 100% of points at one institute and 96%, 88%, 89%, and 100% of points at the other institution passed TG-53 evaluation criteria in the outer beam, penumbra, inner beam, and buildup regions respectively. Poorer results in the inner beam regions at one institute are attributed to the mismatch of the measured profiles at shallow depths with the "golden beam data." For validation of monitor unit (MU) calculations, the mean difference between measured and calculated TSFs was less than 0.5%; test cases involving physical wedges had, in general, differences of more than 1%. The mean difference between point measurements performed in inhomogeneous phantoms and Eclipse was 2.1% (5.3% maximum) and all differences were within TG-53 guidelines of 7%. By intent, the methods and evaluation techniques were similar to those in a previous investigation involving another convolution-superposition photon-beam dose calculation algorithm in another TPS, so that the current work permitted an independent comparison between the two algorithms for which results have been provided.
Assuntos
Algoritmos , Modelos Biológicos , Fótons/uso terapêutico , Radiometria/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Carga Corporal (Radioterapia) , Simulação por Computador , Humanos , Aceleradores de Partículas , Dosagem Radioterapêutica , Eficiência Biológica Relativa , Espalhamento de RadiaçãoRESUMO
OBJECTIVE: To explore the possible relationship between single nucleotide polymorphisms (SNP) in candidate genes encoding DNA damage recognition/repair/response and steroid metabolism proteins with respect to clinical radiation toxicity in a retrospective cohort of patients previously treated with three-dimensional conformal radiotherapy (3-DCRT) for prostate cancer. EXPERIMENTAL DESIGN: One hundred twenty-four patients with prostate cancer underwent 3-DCRT at our institution between September 1996 and December 2000. Of these, 83 consented for follow-up of blood sampling and SNP analysis. Twenty-eight patients were documented as having experienced grade >/=2 late bladder or rectal toxicity (scoring system of Radiation Therapy Oncology Group) on at least one follow-up visit. We analyzed 49 SNPs in BRCA1, BRCA2, ESR1, XRCC1, XRCC2, XRCC3, NBN, RAD51, RAD52, LIG4, ATM, BCL2, TGFB1, MSH6, ERCC2, XPF, NR3C1, CYP1A1, CYP2C9, CYP2C19, CYP3A5, CYP2D6, CYP11B2, and CYP17A1 genes using the Pyrosequencing technique. RESULTS: Significant univariate associations with late rectal or bladder toxicity (grade >/=2) were found for XRCC3 (A>G 5' untranslated region NT 4541), LIG4 (T>C Asp(568)Asp), MLH1 (C>T, Val(219)Ile), CYP2D6*4 (G>A splicing defect), mean rectal and bladder dose, dose to 30% of rectum or bladder, and age <60 years. On Cox multivariate analysis, significant associations with toxicity were found for LIG4 (T>C, Asp(568)Asp), ERCC2 (G>A, Asp(711)Asp), CYP2D6*4 (G>A, splicing defect), mean bladder dose >60 Gy, and dose to 30% of rectal volume >75 Gy. CONCLUSIONS: In this study, we identified SNPs in LIG4, ERCC2, and CYP2D6 genes as putative markers to predict individuals at risk for complications arising from radiation therapy in prostate cancer.